Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 87 entries
Sorted by: Best Match Show Resources per page
Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.

Bioorganic & medicinal chemistry

Wang A, Xu S, Chai Y, Xia G, Wang B, Lv K, Wang D, Qin X, Jiang B, Wu W, Liu M, Lu Y.
PMID: 34861474
Bioorg Med Chem. 2021 Nov 25;53:116529. doi: 10.1016/j.bmc.2021.116529. Epub 2021 Nov 25.

Three series of novel nitrofuran-1,3,4-oxadiazole hybrids were designed and synthesized as new anti-TB agents. The structure activity relationship study indicated that the linkers and the substituents on the oxadiazole moiety greatly influence the activity, and the substituted benzenes are...

Cite
Wang A, Xu S, Chai Y, et al. Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents. Bioorg Med Chem. 2021;53:116529doi: 10.1016/j.bmc.2021.116529.
Wang, A., Xu, S., Chai, Y., Xia, G., Wang, B., Lv, K., Wang, D., Qin, X., Jiang, B., Wu, W., Liu, M., & Lu, Y. (2021). Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents. Bioorganic & medicinal chemistry, 53116529. https://doi.org/10.1016/j.bmc.2021.116529
Wang, Apeng, et al. "Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents." Bioorganic & medicinal chemistry vol. 53 (2021): 116529. doi: https://doi.org/10.1016/j.bmc.2021.116529
Wang A, Xu S, Chai Y, Xia G, Wang B, Lv K, Wang D, Qin X, Jiang B, Wu W, Liu M, Lu Y. Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents. Bioorg Med Chem. 2021 Nov 25;53:116529. doi: 10.1016/j.bmc.2021.116529. Epub 2021 Nov 25. PMID: 34861474.
Copy Download .nbib Format: NLM
Synthesis, antitubercular, antimicrobial activities and molecular docking study of quinoline bearing dihydropyrimidines.

Bioorganic chemistry

Desai NC, Kotadiya GM, Jadeja KA, Shah KN, Malani AH, Manga V, Vani T.
PMID: 34329996
Bioorg Chem. 2021 Oct;115:105173. doi: 10.1016/j.bioorg.2021.105173. Epub 2021 Jul 15.

In order to develop the antimicrobial and antitubercular agents, we have derived quinoline bearing dihydropyrimidine analogues 5a-o and structures of these compounds were determined by spectroscopic techniques. Further, we have calculated the molecular properties prediction and drug-likeness by Molinspiration...

Cite
Desai NC, Kotadiya GM, Jadeja KA, et al. Synthesis, antitubercular, antimicrobial activities and molecular docking study of quinoline bearing dihydropyrimidines. Bioorg Chem. 2021;115:105173doi: 10.1016/j.bioorg.2021.105173.
Desai, N. C., Kotadiya, G. M., Jadeja, K. A., Shah, K. N., Malani, A. H., Manga, V., & Vani, T. (2021). Synthesis, antitubercular, antimicrobial activities and molecular docking study of quinoline bearing dihydropyrimidines. Bioorganic chemistry, 115105173. https://doi.org/10.1016/j.bioorg.2021.105173
Desai, Nisheeth C, et al. "Synthesis, antitubercular, antimicrobial activities and molecular docking study of quinoline bearing dihydropyrimidines." Bioorganic chemistry vol. 115 (2021): 105173. doi: https://doi.org/10.1016/j.bioorg.2021.105173
Desai NC, Kotadiya GM, Jadeja KA, Shah KN, Malani AH, Manga V, Vani T. Synthesis, antitubercular, antimicrobial activities and molecular docking study of quinoline bearing dihydropyrimidines. Bioorg Chem. 2021 Oct;115:105173. doi: 10.1016/j.bioorg.2021.105173. Epub 2021 Jul 15. PMID: 34329996.
Copy Download .nbib Format: NLM
Increased diversity, fungal burden, and virulence of oral Candida spp. in patients undergoing anti-tuberculosis treatment.

Microbial pathogenesis

Orlandini RK, Rocha ACSD, Silva GA, Watanabe E, Motta ACF, Silva-Lovato CH, Oliveira VC, Bollela VR, Lourenço AG.
PMID: 34742893
Microb Pathog. 2021 Dec;161:105280. doi: 10.1016/j.micpath.2021.105280. Epub 2021 Nov 04.

Some studies have demonstrated a high prevalence of Candida species in patients with tuberculosis (TB). This is most likely due to long-term antimicrobial therapy. To date, no longitudinal studies addressed the effects of anti-TB treatment on the fungal burden...

Cite
Orlandini RK, Rocha ACSD, Silva GA, et al. Increased diversity, fungal burden, and virulence of oral Candida spp. in patients undergoing anti-tuberculosis treatment. Microb Pathog. 2021;161:105280doi: 10.1016/j.micpath.2021.105280.
Orlandini, R. K., Rocha, A. C. S. D., Silva, G. A., Watanabe, E., Motta, A. C. F., Silva-Lovato, C. H., Oliveira, V. C., Bollela, V. R., & Lourenço, A. G. (2021). Increased diversity, fungal burden, and virulence of oral Candida spp. in patients undergoing anti-tuberculosis treatment. Microbial pathogenesis, 161105280. https://doi.org/10.1016/j.micpath.2021.105280
Orlandini, Renata Klemp, et al. "Increased diversity, fungal burden, and virulence of oral Candida spp. in patients undergoing anti-tuberculosis treatment." Microbial pathogenesis vol. 161 (2021): 105280. doi: https://doi.org/10.1016/j.micpath.2021.105280
Orlandini RK, Rocha ACSD, Silva GA, Watanabe E, Motta ACF, Silva-Lovato CH, Oliveira VC, Bollela VR, Lourenço AG. Increased diversity, fungal burden, and virulence of oral Candida spp. in patients undergoing anti-tuberculosis treatment. Microb Pathog. 2021 Dec;161:105280. doi: 10.1016/j.micpath.2021.105280. Epub 2021 Nov 04. PMID: 34742893.
Copy Download .nbib Format: NLM
A Comparative Study of 1D Descriptors Supported CoMFA and CoMSIA QSAR Models to Gain Novel Insights into 1,2,4-Triazoles Acting As Antitubercular Agents.

Current computer-aided drug design

Ray R, Shenoy GG, Kumar TNVG.
PMID: 32116196
Curr Comput Aided Drug Des. 2021;17(2):281-293. doi: 10.2174/1573409916666200302115432.

BACKGROUND: Tuberculosis is one of the leading causes of deaths due to infectious disease worldwide. There is an urgent need for developing new drugs due to the rising incidents of drug resistance. Previously, triazole molecules showing antitubercular activity, were...

Cite
Ray R, Shenoy GG, Kumar TNVG. A Comparative Study of 1D Descriptors Supported CoMFA and CoMSIA QSAR Models to Gain Novel Insights into 1,2,4-Triazoles Acting As Antitubercular Agents. Curr Comput Aided Drug Des. 2021;17(2):281-293doi: 10.2174/1573409916666200302115432.
Ray, R., Shenoy, G. G., & Kumar, T. N. V. G. (2021). A Comparative Study of 1D Descriptors Supported CoMFA and CoMSIA QSAR Models to Gain Novel Insights into 1,2,4-Triazoles Acting As Antitubercular Agents. Current computer-aided drug design, 17(2), 281-293. https://doi.org/10.2174/1573409916666200302115432
Ray, Rajdeep, et al. "A Comparative Study of 1D Descriptors Supported CoMFA and CoMSIA QSAR Models to Gain Novel Insights into 1,2,4-Triazoles Acting As Antitubercular Agents." Current computer-aided drug design vol. 17,2 (2021): 281-293. doi: https://doi.org/10.2174/1573409916666200302115432
Ray R, Shenoy GG, Kumar TNVG. A Comparative Study of 1D Descriptors Supported CoMFA and CoMSIA QSAR Models to Gain Novel Insights into 1,2,4-Triazoles Acting As Antitubercular Agents. Curr Comput Aided Drug Des. 2021;17(2):281-293. doi: 10.2174/1573409916666200302115432. PMID: 32116196.
Copy Download .nbib Format: NLM
Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.

Bioorganic & medicinal chemistry

Wu Y, Cheung CY, Zhou Y, Wang Z, Tu Z, Cook GM, Lu X.
PMID: 34624820
Bioorg Med Chem. 2021 Nov 01;49:116426. doi: 10.1016/j.bmc.2021.116426. Epub 2021 Sep 27.

With the emergence of multidrug-resistant strains of Mycobacterium tuberculosis (MDR-TB) and extensive drug-resistant strains (XDR-TB), there is an urgent need to develop novel drugs for the treatment of tuberculosis. Here, we designed and synthesized a series of 5-methylpyrimidopyridone analogues...

Cite
Wu Y, Cheung CY, Zhou Y, et al. Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents. Bioorg Med Chem. 2021;49:116426doi: 10.1016/j.bmc.2021.116426.
Wu, Y., Cheung, C. Y., Zhou, Y., Wang, Z., Tu, Z., Cook, G. M., & Lu, X. (2021). Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents. Bioorganic & medicinal chemistry, 49116426. https://doi.org/10.1016/j.bmc.2021.116426
Wu, Yu, et al. "Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents." Bioorganic & medicinal chemistry vol. 49 (2021): 116426. doi: https://doi.org/10.1016/j.bmc.2021.116426
Wu Y, Cheung CY, Zhou Y, Wang Z, Tu Z, Cook GM, Lu X. Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents. Bioorg Med Chem. 2021 Nov 01;49:116426. doi: 10.1016/j.bmc.2021.116426. Epub 2021 Sep 27. PMID: 34624820.
Copy Download .nbib Format: NLM
Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents.

Journal of medicinal chemistry

Fan D, Wang B, Stelitano G, Savková K, Shi R, Huszár S, Han Q, Mikušová K, Chiarelli LR, Lu Y, Qiao C.
PMID: 34609861
J Med Chem. 2021 Oct 14;64(19):14526-14539. doi: 10.1021/acs.jmedchem.1c01049. Epub 2021 Oct 05.

The benzothiazinone (BTZ) scaffold compound PBTZ169 kills

Cite
Fan D, Wang B, Stelitano G, et al. Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents. J Med Chem. 2021;64(19):14526-14539doi: 10.1021/acs.jmedchem.1c01049.
Fan, D., Wang, B., Stelitano, G., Savková, K., Shi, R., Huszár, S., Han, Q., Mikušová, K., Chiarelli, L. R., Lu, Y., & Qiao, C. (2021). Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents. Journal of medicinal chemistry, 64(19), 14526-14539. https://doi.org/10.1021/acs.jmedchem.1c01049
Fan, Dongguang, et al. "Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents." Journal of medicinal chemistry vol. 64,19 (2021): 14526-14539. doi: https://doi.org/10.1021/acs.jmedchem.1c01049
Fan D, Wang B, Stelitano G, Savková K, Shi R, Huszár S, Han Q, Mikušová K, Chiarelli LR, Lu Y, Qiao C. Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents. J Med Chem. 2021 Oct 14;64(19):14526-14539. doi: 10.1021/acs.jmedchem.1c01049. Epub 2021 Oct 05. PMID: 34609861.
Copy Download .nbib Format: NLM
Deciphering the Structural Requirements of Nucleoside Bisubstrate Analogues for Inhibition of MbtA in Mycobacterium tuberculosis: A FB-QSAR Study and Combinatorial Library Generation for Identifying Potential Hits.

Molecular informatics

Maganti L, Das SK, Mascarenhas NM, Ghoshal N.
PMID: 27468106
Mol Inform. 2011 Oct;30(10):863-72. doi: 10.1002/minf.201100056. Epub 2011 Sep 07.

The re-emergence of tuberculosis infections, which are resistant to conventional drug therapy, has steadily risen in the last decade. Inhibitors of aryl acid adenylating enzyme known as MbtA, involved in siderophore biosynthesis in Mycobacterium tuberculosis, are being explored as...

Cite
Maganti L, Das SK, Mascarenhas NM, et al. Deciphering the Structural Requirements of Nucleoside Bisubstrate Analogues for Inhibition of MbtA in Mycobacterium tuberculosis: A FB-QSAR Study and Combinatorial Library Generation for Identifying Potential Hits. Mol Inform. 2011;30(10):863-72doi: 10.1002/minf.201100056.
Maganti, L., Das, S. K., Mascarenhas, N. M., & Ghoshal, N. (2011). Deciphering the Structural Requirements of Nucleoside Bisubstrate Analogues for Inhibition of MbtA in Mycobacterium tuberculosis: A FB-QSAR Study and Combinatorial Library Generation for Identifying Potential Hits. Molecular informatics, 30(10), 863-72. https://doi.org/10.1002/minf.201100056
Maganti, Lakshmi, et al. "Deciphering the Structural Requirements of Nucleoside Bisubstrate Analogues for Inhibition of MbtA in Mycobacterium tuberculosis: A FB-QSAR Study and Combinatorial Library Generation for Identifying Potential Hits." Molecular informatics vol. 30,10 (2011): 863-72. doi: https://doi.org/10.1002/minf.201100056
Maganti L, Das SK, Mascarenhas NM, Ghoshal N. Deciphering the Structural Requirements of Nucleoside Bisubstrate Analogues for Inhibition of MbtA in Mycobacterium tuberculosis: A FB-QSAR Study and Combinatorial Library Generation for Identifying Potential Hits. Mol Inform. 2011 Oct;30(10):863-72. doi: 10.1002/minf.201100056. Epub 2011 Sep 07. PMID: 27468106.
Copy Download .nbib Format: NLM
Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents.

ACS medicinal chemistry letters

Yokokawa F, Wang G, Chan WL, Ang SH, Wong J, Ma I, Rao SP, Manjunatha U, Lakshminarayana SB, Herve M, Kounde C, Tan BH, Thayalan P, Ng SH, Nanjundappa M, Ravindran S, Gee P, Tan M, Wei L, Goh A, Chen PY, Lee KS, Zhong C, Wagner T, Dix I, Chatterjee AK, Pethe K, Kuhen K, Glynne R, Smith P, Bifani P, Jiricek J.
PMID: 24900693
ACS Med Chem Lett. 2013 Apr 01;4(5):451-5. doi: 10.1021/ml400071a. eCollection 2013 May 09.

Tetrahydropyrazolo[1,5-a]pyrimidine scaffold was identified as a hit series from a Mycobacterium tuberculosis (Mtb) whole cell high through-put screening (HTS) campaign. A series of derivatives of this class were synthesized to evaluate their structure-activity relationship (SAR) and structure-property relationship (SPR)....

Cite
Yokokawa F, Wang G, Chan WL, et al. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. ACS Med Chem Lett. 2013;4(5):451-5doi: 10.1021/ml400071a.
Yokokawa, F., Wang, G., Chan, W. L., Ang, S. H., Wong, J., Ma, I., Rao, S. P., Manjunatha, U., Lakshminarayana, S. B., Herve, M., Kounde, C., Tan, B. H., Thayalan, P., Ng, S. H., Nanjundappa, M., Ravindran, S., Gee, P., Tan, M., Wei, L., Goh, A., Chen, P. Y., Lee, K. S., Zhong, C., Wagner, T., Dix, I., Chatterjee, A. K., Pethe, K., Kuhen, K., Glynne, R., Smith, P., Bifani, P., & Jiricek, J. (2013). Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. ACS medicinal chemistry letters, 4(5), 451-5. https://doi.org/10.1021/ml400071a
Yokokawa, Fumiaki, et al. "Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents." ACS medicinal chemistry letters vol. 4,5 (2013): 451-5. doi: https://doi.org/10.1021/ml400071a
Yokokawa F, Wang G, Chan WL, Ang SH, Wong J, Ma I, Rao SP, Manjunatha U, Lakshminarayana SB, Herve M, Kounde C, Tan BH, Thayalan P, Ng SH, Nanjundappa M, Ravindran S, Gee P, Tan M, Wei L, Goh A, Chen PY, Lee KS, Zhong C, Wagner T, Dix I, Chatterjee AK, Pethe K, Kuhen K, Glynne R, Smith P, Bifani P, Jiricek J. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. ACS Med Chem Lett. 2013 Apr 01;4(5):451-5. doi: 10.1021/ml400071a. eCollection 2013 May 09. PMID: 24900693; PMCID: PMC4027361.
Copy Download .nbib Format: NLM
Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents.

Indian journal of pharmaceutical sciences

Mathew B, Suresh J, Mathew GE, Sonia G, Krishnan GK.
PMID: 25425753
Indian J Pharm Sci. 2014 Sep;76(5):401-6.

A series of novel N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimines (Fa-e) were synthesized and evaluated for antitubercular activity against Mycobacterium tuberculosis (H37Rv) strain by using alamar blue assay. The synthesized compounds were characterized based on IR, (1)HMR and mass spectral analysis. The...

Cite
Mathew B, Suresh J, Mathew GE, et al. Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents. Indian J Pharm Sci. 2014;76(5):401-6
Mathew, B., Suresh, J., Mathew, G. E., Sonia, G., & Krishnan, G. K. (2014). Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents. Indian journal of pharmaceutical sciences, 76(5), 401-6.
Mathew, B, et al. "Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents." Indian journal of pharmaceutical sciences vol. 76,5 (2014): 401-6.
Mathew B, Suresh J, Mathew GE, Sonia G, Krishnan GK. Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents. Indian J Pharm Sci. 2014 Sep;76(5):401-6. PMID: 25425753; PMCID: PMC4243256.
Copy Download .nbib Format: NLM
Screening of the antimycobacterial activity of novel lipophilic agents by the modified broth based method.

Journal of clinical tuberculosis and other mycobacterial diseases

Zandhaghighi M, Ghazvini K, Meshkat Z, Rezaee SA, Derakhshan M, Soleimanpour S, Hadizadeh F.
PMID: 31723679
J Clin Tuberc Other Mycobact Dis. 2016 Feb 11;3:1-5. doi: 10.1016/j.jctube.2016.01.001. eCollection 2016 May.

Most of the introduced susceptibility methods of

Cite
Zandhaghighi M, Ghazvini K, Meshkat Z, et al. Screening of the antimycobacterial activity of novel lipophilic agents by the modified broth based method. J Clin Tuberc Other Mycobact Dis. 2016;3:1-5doi: 10.1016/j.jctube.2016.01.001.
Zandhaghighi, M., Ghazvini, K., Meshkat, Z., Rezaee, S. A., Derakhshan, M., Soleimanpour, S., & Hadizadeh, F. (2016). Screening of the antimycobacterial activity of novel lipophilic agents by the modified broth based method. Journal of clinical tuberculosis and other mycobacterial diseases, 31-5. https://doi.org/10.1016/j.jctube.2016.01.001
Zandhaghighi, Mehdi, et al. "Screening of the antimycobacterial activity of novel lipophilic agents by the modified broth based method." Journal of clinical tuberculosis and other mycobacterial diseases vol. 3 (2016): 1-5. doi: https://doi.org/10.1016/j.jctube.2016.01.001
Zandhaghighi M, Ghazvini K, Meshkat Z, Rezaee SA, Derakhshan M, Soleimanpour S, Hadizadeh F. Screening of the antimycobacterial activity of novel lipophilic agents by the modified broth based method. J Clin Tuberc Other Mycobact Dis. 2016 Feb 11;3:1-5. doi: 10.1016/j.jctube.2016.01.001. eCollection 2016 May. PMID: 31723679; PMCID: PMC6850257.
Copy Download .nbib Format: NLM
Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents.

The open medicinal chemistry journal

Sager AA, Abood ZS, El-Amary WM, Bensaber SM, Al-Sadawe IA, Ermeli NB, Mohamed SB, Al-Forgany M, Mrema IA, Erhuma M, Hermann A, Gbaj AM.
PMID: 29854013
Open Med Chem J. 2018 Apr 30;12:48-59. doi: 10.2174/1874104501812010048. eCollection 2018.

BACKGROUND: Tuberculosis (TB) is the second important cause of death worldwide caused by a bacterium called METHODS: Our main aims are to design and synthesize analogues of TLM as new lead molecules which could be a possible anti-TB candidate....

Cite
Sager AA, Abood ZS, El-Amary WM, et al. Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents. Open Med Chem J. 2018;12:48-59doi: 10.2174/1874104501812010048.
Sager, A. A., Abood, Z. S., El-Amary, W. M., Bensaber, S. M., Al-Sadawe, I. A., Ermeli, N. B., Mohamed, S. B., Al-Forgany, M., Mrema, I. A., Erhuma, M., Hermann, A., & Gbaj, A. M. (2018). Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents. The open medicinal chemistry journal, 1248-59. https://doi.org/10.2174/1874104501812010048
Sager, Asma A, et al. "Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents." The open medicinal chemistry journal vol. 12 (2018): 48-59. doi: https://doi.org/10.2174/1874104501812010048
Sager AA, Abood ZS, El-Amary WM, Bensaber SM, Al-Sadawe IA, Ermeli NB, Mohamed SB, Al-Forgany M, Mrema IA, Erhuma M, Hermann A, Gbaj AM. Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents. Open Med Chem J. 2018 Apr 30;12:48-59. doi: 10.2174/1874104501812010048. eCollection 2018. PMID: 29854013; PMCID: PMC5944127.
Copy Download .nbib Format: NLM
Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.

Tuberculosis and respiratory diseases

Kim HW, Kim JS.
PMID: 29332319
Tuberc Respir Dis (Seoul). 2018 Jan;81(1):6-12. doi: 10.4046/trd.2017.0052.

The role of the treatment for latent tuberculosis infection (LTBI) has been underscored in the intermediate tuberculosis (TB) burden countries like South Korea. LTBI treatment is recommended only for patients at risk for progression to active TB-those with frequent...

Cite
Kim HW, Kim JS. Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy. Tuberc Respir Dis (Seoul). 2018;81(1):6-12doi: 10.4046/trd.2017.0052.
Kim, H. W., & Kim, J. S. (2018). Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy. Tuberculosis and respiratory diseases, 81(1), 6-12. https://doi.org/10.4046/trd.2017.0052
Kim, Hyung Woo, and Kim, Ju Sang. "Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy." Tuberculosis and respiratory diseases vol. 81,1 (2018): 6-12. doi: https://doi.org/10.4046/trd.2017.0052
Kim HW, Kim JS. Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy. Tuberc Respir Dis (Seoul). 2018 Jan;81(1):6-12. doi: 10.4046/trd.2017.0052. PMID: 29332319; PMCID: PMC5771748.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 87 entries